Amneal Pharmaceuticals (NASDAQ:AMRX) Issues FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 0.930-1.030 for the period, compared to the consensus EPS estimate of 0.920. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Amneal Pharmaceuticals Stock Down 4.7%

Amneal Pharmaceuticals stock traded down $0.68 during mid-day trading on Friday, reaching $13.81. The company had a trading volume of 3,936,087 shares, compared to its average volume of 2,818,148. The firm has a market cap of $4.34 billion, a price-to-earnings ratio of 690.85 and a beta of 1.36. The company has a 50 day moving average of $13.72 and a 200-day moving average of $11.69. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $15.42.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on AMRX shares. Truist Financial set a $15.00 price objective on Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Piper Sandler reiterated an “overweight” rating and set a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Barclays began coverage on Amneal Pharmaceuticals in a research note on Monday, December 8th. They issued an “overweight” rating and a $15.00 price objective on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.80.

Institutional Investors Weigh In On Amneal Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP raised its stake in shares of Amneal Pharmaceuticals by 5.3% in the third quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after acquiring an additional 624,609 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amneal Pharmaceuticals by 3.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock worth $70,681,000 after purchasing an additional 177,906 shares during the last quarter. Morgan Stanley lifted its holdings in Amneal Pharmaceuticals by 37.5% during the 4th quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Amneal Pharmaceuticals by 14.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after buying an additional 558,877 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Amneal Pharmaceuticals by 3.4% in the 4th quarter. State Street Corp now owns 4,110,410 shares of the company’s stock valued at $51,791,000 after buying an additional 136,662 shares during the period. Institutional investors and hedge funds own 31.82% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.